Non-Small Cell Lung Cancer Drug Market Size, Share, Trends, Growth and Forecast 2032

Non-Small Cell Lung Cancer Drug Industry Prospective:

The global non-small cell lung cancer drug market size was evaluated at $20.1 billion in 2023 and is slated to hit $70 billion by the end of 2032 with a CAGR of nearly 11% between 2024 and 2032.

Request Free Sample

Non-Small Cell Lung Cancer Drug Market: Overview

Non-small cell lung cancer is a common kind of lung cancer, and a slew of drugs are used for treating this ailment. There are a few kinds of drugs that are used for treating non-small cell lung cancer, and they include chemotherapy, immunotherapy, targeted therapy, anti-angiogenesis drugs, and combination drug therapies.  

Key Insights

• As per the analysis shared by our research analyst, the global non-small cell lung cancer drug market is projected to expand annually at the annual growth rate of around 11% over the forecast timespan (2024-2032)
• In terms of revenue, the global non-small cell lung cancer drug market size was evaluated at nearly $20.1 billion in 2023 and is expected to reach $70 billion by 2032.
• The global non-small cell lung cancer drug market is anticipated to grow rapidly over the forecast timeline owing to a surge in the cases of non-small lung cancer patients in both emerging economies and developed countries.
• In terms of drug class, the targeted treatments segment is slated to register the highest CAGR over the forecast period.
• Based on route of administration, the intravenous segment is predicted to contribute majorly towards segmental space in the upcoming years.
• Based on distribution channel, the hospital pharmacies segment is likely to lead the global market growth in the ensuing years.
• Region-wise, the European non-small cell lung cancer drug industry is projected to register the fastest CAGR during the assessment timespan.

Non-Small Cell Lung Cancer Drug Market: Growth Factors

Innovations in targeted drug therapies can propel the expansion of the global market over 2024-2032

A surge in the cases of non-small lung cancer patients in both emerging economies and developed countries will steer the expansion of the global non-small lung cancer drug market in the near future. Reportedly, smoking and air pollution are a few of the key causes of non-small lung cancer globally.

Moreover, breakthroughs in the targeted treatments, including ALK and EGFR, have brought a paradigm shift in treating non-small lung cancer patients, thereby driving the global market trends.

Escalating elderly populace and breakthroughs in immunotherapy medicines such as PD-L1 and PD-1 inhibitors will proliferate the global market size.

Non-Small Cell Lung Cancer Drug Market: Restraints

Escalating costs of drugs used for treating lung cancer can restrict the global industry surge in the coming years  

Cancer cells have developed resistance to drugs for certain kinds of targeted drug treatments, thereby reducing its long-term effect. This, in turn, can hinder the global non-small cell lung cancer drug industry.

A massive increment in the prices of cancer treatment, along with the side effects of these treatments, can hamper the global industry surge.

Non-Small Cell Lung Cancer Drug Market: Opportunities

Favorable legislation promoting the use of personalized medicines for treating non-small cell lung cancer to boost the global market trends  

Surging healthcare expenditures and supportive laws related to the use of precision drugs to treat non-small cell lung cancer are likely to open new growth horizons for the global non-small cell lung cancer drug market.

Escalating awareness about various kinds of lung cancer and detection of cancer at the initial phase can propel the demand for non-small cell lung cancer drugs.  

Non-Small Cell Lung Cancer Drug Market: Challenges

Huge raw component costs are likely to slow down the global industry growth in the ensuing years

Regulatory obstacles related to the drug approval process and intellectual property issues can obstruct the global non-small cell lung cancer industry progression. High costs of drugs and high raw material prices can further challenge the global industry surge in the coming years.

Non-Small Cell Lung Cancer Drug Market: Segmentation

The global non-small cell lung cancer drug market is divided into drug class, route of administration, distribution channel, and region.                                             

In terms of drug class, the non-small cell lung cancer drug market across the globe is segmented into targeted treatments, chemotherapy, and immunotherapy segments.

Apparently, the targeted treatments segment, which gathered nearly 53% of the global market earnings in 2023, is expected to record the fastest CAGR in the coming eight years, subject to the launch of new medicines aimed at targeting particular molecular changes in cancer cells.

Growing use of personalized medicine based on the genetic profile of patients will further drive the segmental surge. 

Based on route of administration, the global non-small cell lung cancer drug industry is divided into subcutaneous, oral, and intravenous segments.

Apparently, the intravenous segment, which dominated the global industry size in 2023, is anticipated to account majorly towards the segmental expansion in the analysis timeline.

This can be a result of swift drug delivery, precise control of drug dosage, and treatment of non-small cell lung cancer in the advanced phase.

On the basis of distribution channel, the global non-small cell lung cancer drug market is bifurcated into online pharmacies, hospital pharmacies, and retail pharmacies segments.

Moreover, the hospital pharmacies segment, which led the global market share in 2023, is expected to lead the global market growth in the forecast timespan.

The segmental expansion in the coming eight years can be owing to complex therapy regimes, easy access to new modes of treatments, and integration of hospital pharmacies with healthcare service providers.

Non-Small Cell Lung Cancer Drug Market: Report Scope

Non-Small-Cell Lung Cancer Drug Market: Regional Insights

North America is projected to maintain leading status in the global market over the assessment timeline

North America, which accounted for about 64% of the global non-small cell lung cancer drug market size in 2023, is predicted to establish a leading position in the global market in the forecasting timeline.

Furthermore, the regional market uplift in the coming decade can be a result of the presence of giant players in countries such as the U.S.

Availability of strong healthcare infrastructure facilities in countries such as Canada and the U.S. will bolster the growth of the market in the U.S.

Additionally, easy acceptance of new drug treatments and an increase in large allocation of funds for research activities will spur the market growth in the region.  

The European non-small cell lung cancer drug industry is expected to register the fastest CAGR annually in the forecasting timespan.

The elevation of the industry in Europe can be a result of the availability of excellent healthcare amenities and favorable laws enforced in the continent.

Additionally, growing awareness about the effectiveness of the drugs in treating lung cancer among the European population will steer the growth of the industry in the continent.

Key Developments

• In August 2024, the U.S. FDA approved lazertinib along with amivantamab-vmjw for treating non-small cell lung cancer in the advanced phase.

Non-Small-Cell Lung Cancer Drug Market: Competitive Space

The global small cell lung cancer drug market profiles key players such as:

• Novartis
• AstraZeneca plc
• Merck & Co.Inc.
• Jazz Pharmaceuticals plc
• Bristol-Myers Squibb Company
• Chugai Pharmaceutical Co.Ltd.
• Roche Holding AG
• Ipsen
• G1 TherapeuticsInc.
• Amgen Inc.
• Pfizer
• PharmaMar S.A.

The global non-small cell lung cancer drug market is segmented as follows:

By Drug Class

• Targeted Treatments
• Chemotherapy
• Immunotherapy

By Route of Administration

• Subcutaneous
• Oral
• Intravenous

By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa